EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Teva Pharmaceutical Industries's Enterprise Value is $31,233 Mil.
Teva Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $405 Mil. Therefore, Teva Pharmaceutical Industries's EV-to-EBIT for today is 77.12.
The historical rank and industry rank for Teva Pharmaceutical Industries's EV-to-EBIT or its related term are showing as below:
TEVA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -99.89 Med: 5.78 Max: 87.24
Current: 76.99
During the past 13 years, the highest EV-to-EBIT of Teva Pharmaceutical Industries was 87.24. The lowest was -99.89. And the median was 5.78.
TEVA's EV-to-EBIT is ranked worse than 92.81% of 668
companies
in the Drug Manufacturers industry
Industry Median: 16.995
vs TEVA: 76.99
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Teva Pharmaceutical Industries's Enterprise Value for the quarter that ended in Dec. 2023 was $29,251 Mil.
Teva Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $405 Mil. Teva Pharmaceutical Industries's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.38%.
Teva Pharmaceutical Industries EV-to-EBIT Historical Data
The historical data trend for Teva Pharmaceutical Industries's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Teva Pharmaceutical Industries Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBIT
-81.96
-9.73
19.43
-13.08
71.16
Teva Pharmaceutical Industries Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBIT
-13.08
-19.15
-22.42
-23.49
71.16
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's EV-to-EBIT falls into.
Teva Pharmaceutical Industries's current Enterprise Value is $31,233 Mil.
Teva Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $405 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Teva Pharmaceutical Industries's Enterprise Value for the quarter that ended in Dec. 2023 was $29,251 Mil.
Teva Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $405 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 